United States

Novartis AG (NVS)

NVS on New York Consolidated

23 Feb 2017
Change (% chg)

$0.60 (+0.78%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Latest Key Developments (Source: Significant Developments)

Novartis says LEE011 (ribociclib) granted FDA priority review
Tuesday, 1 Nov 2016 07:30am EDT 

Novartis Pharmaceuticals Corp:Novartis LEE011 (ribociclib) granted FDA priority review for first-line treatment of HR+/HER2- advanced breast cancer.  Full Article

Novartis Bioventures reports 11.8 pct passive stake in Ra Pharmaceuticals - SEC filing
Monday, 31 Oct 2016 04:51pm EDT 

Novartis Ag :Novartis Bioventures Ltd reports 11.8 percent passive stake in Ra Pharmaceuticals Inc as of Oct. 31 - SEC filing.  Full Article

Genvec says Novartis informed co that it remains engaged on CGF166 program
Thursday, 1 Sep 2016 06:54am EDT 

Genvec Inc : Novartis has informed Genvec that it remains engaged on CGF166 program . Novartis's internal changes are not expected or intended to reduce its support for program Source: (http://bit.ly/2bLXskP ) Further company coverage: [GNVC.O] ((Bangalore.newsroom@thomsonreuters.com;)).  Full Article

U.S. FDA approves Erelzi, a biosimilar to Enbrel
Tuesday, 30 Aug 2016 04:25pm EDT 

U.S. FDA: U.S. FDA approves Erelzi, a biosimilar to Enbrel .Erelzi has been approved as a biosimilar, not as an interchangeable product.  Full Article

Jacobs wins contract for Novartis Biotechnology Center expansion
Thursday, 11 Aug 2016 07:45am EDT 

Jacobs Engineering Group Inc : Jacobs awarded contract for Novartis Biotechnology Center expansion in France . $100 million expansion project is scheduled to be completed in four years .Providing engineering, procurement, construction management services to increase site's production capacity by 70 percent.  Full Article

Genvec says FDA lifts hold on clinical trial of hearing loss treatment
Monday, 25 Jul 2016 07:30am EDT 

Genvec Inc :Notified by Novartis that FDA has lifted clinical hold on phase 1/2 clinical trial of CGF166 in patients with severe to profound hearing loss.  Full Article

Novartis to spend extra $200 mln to push Entresto - CEO
Tuesday, 19 Jul 2016 01:55am EDT 

Novartis CEO says on call with journalists: Novartis ceo says expects Alcon to return to growth this year . Novartis says anticipates more difficult u.s. Pricing environment . Novartis ceo says planning for u.s. Environment without price increases . Novartis ceo says expects EMA drugs approval agency to leave london after brexit vote . Novartis ceo says entresto to be strong in u.s. And europe markets . Novartis ceo says brexit vote has no impact on our willingness to invest in britain . Novartis ceo says to spend additional $200 million on entresto push in h2 . Novartis ceo says sees cosentyx peak sales likely over $4 billion . Novartis ceo says don't see big impact on industry from Brexit . Novartis says no change on Roche stake, will look to exit if opportunity exists .Extra Entresto spending could cost 1-2 percent of core operating income.  Full Article

FDA approves Roche's Xolair for allergic asthma in children
Thursday, 7 Jul 2016 04:40pm EDT 

Genentech :FDA approves xolair for allergic asthma in children.  Full Article

Xencor enteres into collaboration and license agreement with Novartis
Tuesday, 28 Jun 2016 01:15am EDT 

Xencor Inc : Xencor announces strategic collaboration for bispecific programs, including XMAB 14045 and XMAB 13676 . Has entered into a collaboration and license agreement with Novartis to develop and commercialize novel therapeutics . Parties will collaborate and share development costs for worldwide development of XMAB14045 and XMAB13676, with Xencor . Will receive a $150 million upfront payment and is eligible to receive clinical, regulatory and sales milestone payments for successful programs . Says eligible to receive tiered, low double-digit royalties for sales of XMAB14045 and XMAB13676 outside of U.S. . Novartis to receive worldwide rights to co's bispecific technology to develop and commercialize four additional targets selected by Novartis .Says Novartis will receive a worldwide non-exclusive license to use Xencor's XMAB FC technologies in up to ten molecules.  Full Article

Spectrum Pharmaceuticals' unit, Allos Therapeutics and Sandoz enter settlement agreement
Thursday, 9 Jun 2016 06:15am EDT 

Spectrum Pharmaceuticals Inc : On June 8, 2016, co's unit , Allos Therapeutics and Sandoz Inc entered into a settlement agreement . Spectrum Pharmaceuticals Inc says settlement agreement to resolve patent litigation relating to folotyn . Sandoz will be permitted to market generic version of folotyn in U.S on November 15, 2022 or earlier under certain circumstances . Details of settlement confidential, parties will submit agreement to ftc and department of justice . Spectrum Pharmaceuticals says parties will request that court enter an order, in which it will dismiss company's litigation against sandoz .Spectrum Pharmaceuticals Inc says company's litigation against one other generic filer continues.  Full Article

More From Around the Web


Novartis cancer drug Zykadia gets FDA priority review

ZURICH The U.S. Food and Drug Administration (FDA) has granted priority review to Novartis drug Zykadia as a first-line treatment for some lung cancer patients, the Swiss drugmaker said on Thursday.